Literature DB >> 17064684

Long-term angiotensin II AT1 receptor inhibition produces adipose tissue hypotrophy accompanied by increased expression of adiponectin and PPARgamma.

Stefan Zorad1, Jing-tao Dou, Julius Benicky, Daniel Hutanu, Katarina Tybitanclova, Jin Zhou, Juan M Saavedra.   

Abstract

To clarify the mechanism of the effects of angiotensin II AT(1) receptor antagonists on adipose tissue, we treated 8 week-old male Wistar Kyoto rats with the angiotensin II AT(1) receptor antagonist Candesartan cilexetil (10 mg/kg/day) for 18 weeks. Candesartan cilexetil reduced body weight gain, decreased fat tissue mass due to hypotrophy of epididymal and retroperitoneal adipose tissue and decreased adipocyte size without changing the number of adipocytes. Candesartan cilexetil decreased serum leptin levels and epididymal leptin mRNA, increased serum adiponectin levels and epididymal adiponectin mRNA, decreased epididymal tumor necrosis factor alpha (TNFalpha) mRNA, and increased fatty acid synthase mRNA. Considered free of peroxisome proliferator-activated receptor gamma (PPARgamma) agonist activity, Candesartan cilexetil increased epididymal expression of PPARgamma mRNA. The effects of Candesartan cilexetil on adipokine production and release may be attributable to PPARgamma activation and/or decrease in adipocyte cell size. In addition, Candesartan cilexetil treatment increased the expression of epididymal angiotensin II AT(2) receptor mRNA and protein and decreased the expression of renin receptor mRNA. These results suggest that Candesartan cilexetil influences lipid metabolism in adipose tissue by promoting adipose tissue rearrangement and modulating adipokine expression and release. These effects are probably consequences of local angiotensin II AT(1) receptor inhibition, angiotensin II AT(2) receptor stimulation, and perhaps additional angiotensin II-independent mechanisms. Our results indicate that the activity of local renin-angiotensin system plays an important role in adipose tissue metabolism. The decrease in the pro-inflammatory cytokine TNFalpha and the increase in the anti-inflammatory adipokine adiponectin indicate that Candesartan cilexetil may exert significant anti-inflammatory properties.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17064684      PMCID: PMC1764497          DOI: 10.1016/j.ejphar.2006.08.062

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  62 in total

1.  Primer3 on the WWW for general users and for biologist programmers.

Authors:  S Rozen; H Skaletsky
Journal:  Methods Mol Biol       Date:  2000

2.  A simple method for the isolation and purification of total lipides from animal tissues.

Authors:  J FOLCH; M LEES; G H SLOANE STANLEY
Journal:  J Biol Chem       Date:  1957-05       Impact factor: 5.157

3.  Enlarged subcutaneous abdominal adipocyte size, but not obesity itself, predicts type II diabetes independent of insulin resistance.

Authors:  C Weyer; J E Foley; C Bogardus; P A Tataranni; R E Pratley
Journal:  Diabetologia       Date:  2000-12       Impact factor: 10.122

4.  Angiotensin II infusion increases hepatic triglyceride production via its type 2 receptor in rats.

Authors:  Jianmin Ran; Tsutomu Hirano; Mitsuru Adachi
Journal:  J Hypertens       Date:  2005-08       Impact factor: 4.844

5.  Angiotensin-II-induced oxidative stress elicits hypoadiponectinaemia in rats.

Authors:  Y Hattori; K Akimoto; S S Gross; S Hattori; K Kasai
Journal:  Diabetologia       Date:  2005-04-30       Impact factor: 10.122

6.  PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein.

Authors:  N Maeda; M Takahashi; T Funahashi; S Kihara; H Nishizawa; K Kishida; H Nagaretani; M Matsuda; R Komuro; N Ouchi; H Kuriyama; K Hotta; T Nakamura; I Shimomura; Y Matsuzawa
Journal:  Diabetes       Date:  2001-09       Impact factor: 9.461

7.  Angiotensin II as a trophic factor of white adipose tissue: stimulation of adipose cell formation.

Authors:  P Saint-Marc; L P Kozak; G Ailhaud; C Darimont; R Negrel
Journal:  Endocrinology       Date:  2001-01       Impact factor: 4.736

8.  Peripheral administration of an angiotensin II AT(1) receptor antagonist decreases the hypothalamic-pituitary-adrenal response to isolation Stress.

Authors:  I Armando; A Carranza; Y Nishimura; K L Hoe; M Barontini; J A Terrón; A Falcón-Neri; T Ito; A V Juorio; J M Saavedra
Journal:  Endocrinology       Date:  2001-09       Impact factor: 4.736

9.  Mechanistic differences of various AT1-receptor blockers in isolated vessels of different origin.

Authors:  P Morsing; G Adler; U Brandt-Eliasson; L Karp; K Ohlson; L Renberg; P O Sjöquist; T Abrahamsson
Journal:  Hypertension       Date:  1999-06       Impact factor: 10.190

10.  Renin increases mesangial cell transforming growth factor-beta1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms.

Authors:  Y Huang; S Wongamorntham; J Kasting; D McQuillan; R T Owens; L Yu; N A Noble; W Border
Journal:  Kidney Int       Date:  2006-01       Impact factor: 18.998

View more
  59 in total

Review 1.  Blockade of brain angiotensin II AT1 receptors ameliorates stress, anxiety, brain inflammation and ischemia: Therapeutic implications.

Authors:  Juan M Saavedra; Enrique Sánchez-Lemus; Julius Benicky
Journal:  Psychoneuroendocrinology       Date:  2010-10-29       Impact factor: 4.905

2.  The brain Renin-angiotensin system controls divergent efferent mechanisms to regulate fluid and energy balance.

Authors:  Justin L Grobe; Connie L Grobe; Terry G Beltz; Scott G Westphal; Donald A Morgan; Di Xu; Willem J de Lange; Huiping Li; Koji Sakai; Daniel R Thedens; Lisa A Cassis; Kamal Rahmouni; Allyn L Mark; Alan Kim Johnson; Curt D Sigmund
Journal:  Cell Metab       Date:  2010-11-03       Impact factor: 27.287

3.  Weight loss and hypophagia after high-dose AT1-blockade is only observed after high dosing and depends on regular leptin signalling but not blood pressure.

Authors:  Helge Müller-Fielitz; Antonie Markert; Christian Wittmershaus; Friedrich Pahlke; Olaf Jöhren; Walter Raasch
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-02-03       Impact factor: 3.000

4.  Lack of weight gain after angiotensin AT1 receptor blockade in diet-induced obesity is partly mediated by an angiotensin-(1-7)/Mas-dependent pathway.

Authors:  Johanna Schuchard; Martina Winkler; Ines Stölting; Franziska Schuster; Florian M Vogt; Jörg Barkhausen; Christoph Thorns; Robson A Santos; Michael Bader; Walter Raasch
Journal:  Br J Pharmacol       Date:  2015-06-12       Impact factor: 8.739

5.  Double blockade of angiotensin II (AT(1) )-receptors and ACE does not improve weight gain and glucose homeostasis better than single-drug treatments in obese rats.

Authors:  Anja Miesel; Helge Müller-Fielitz; Olaf Jöhren; Florian M Vogt; Walter Raasch
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

Review 6.  Obesity and renovascular disease.

Authors:  Xin Zhang; Lilach O Lerman
Journal:  Am J Physiol Renal Physiol       Date:  2015-06-03

Review 7.  Control of energy balance by the brain renin-angiotensin system.

Authors:  Kristin E Claflin; Justin L Grobe
Journal:  Curr Hypertens Rep       Date:  2015-05       Impact factor: 5.369

8.  Deregulation of adipokines related to target organ damage on resistant hypertension.

Authors:  A R Sabbatini; A P Faria; N R Barbaro; W M Gordo; R G P Modolo; C Pinho; V Fontana; H Moreno
Journal:  J Hum Hypertens       Date:  2013-11-28       Impact factor: 3.012

Review 9.  Opposing tissue-specific roles of angiotensin in the pathogenesis of obesity, and implications for obesity-related hypertension.

Authors:  Nicole K Littlejohn; Justin L Grobe
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2015-10-21       Impact factor: 3.619

10.  PPARs in the Renal Regulation of Systemic Blood Pressure.

Authors:  Tamás Roszer; Mercedes Ricote
Journal:  PPAR Res       Date:  2010-06-08       Impact factor: 4.964

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.